FDA Grants De Novo Marketing Authorization For At-Home Retinal Imaging Device

Notal Vision, a Virginia-based patient-centric ophthalmic remote monitoring services provider, has won de novo marketing authorization from the US FDA for a product that allows patients to keep tabs on their age-related macular degeneration while at home.

MACULAR DEGENERATION
• Source: Shutterstock

The US Food and Drug Administration announced on May 16 it has granted digital health care provider Notal Vision’s de novo marketing authorization for its patient self-operated Scanly Home optical coherence tomography device for monitoring age-related macular degeneration.

Designated by the FDA as a breakthrough device for patients suffering from neovascular, age-related macular degeneration or nvAMD, the leading...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Regulation

More from Policy & Regulation